A new study links GLP-1 drugs like Ozempic to serious eye conditions, including nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to blindness.
Researchers reviewed nine cases where patients developed vision problems after starting semaglutide or similar medications.
While the study does not prove causation, scientists suspect the drugs may contribute to these issues by rapidly lowering blood sugar or affecting optic nerve cells.
Experts call for more research and suggest that adjusting dosage rates might help mitigate potential risks for high-risk patients.